

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of 1

*Complete if Known*

Application Number	<b>New Application</b>
Filing Date	herewith
First Named Inventor	<b>Cournoyer, Richard Leo et al.</b>
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	<b>R0153B-REG</b>

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	US-5,668,145	09-16-1997	Bright, Gene M.	
	A2	US-5,705,646	01-06-1998	Bright, et al.	
	A3	US-5,712,303	01-27-1998	Faraci, et al.	
	A4	US-5,760,225	06-02-1998	Yuan, Jun	
	A5	US-6,200,979 B1	03-13-2001	Bright, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	WO 00/27394 A1	05-18-2000	University College, London (GB)		
	B2	WO 01/58869 A2	08-16-2001	Bristol-Myers Squibb Co. (US)		
	B3	WO 02/16348 A1	02-28-2002	Hennequin, Laurent (GB) (for U.S. only)		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	GRIGORIADIS, Dimitri E., et al., "The CRF Receptor: Structure, Function and Potential for Therapeutic Intervention," <i>Curr. Med. Chem. – Central Nervous System Agents</i> , 2001, pp. 63-97, vol. 1, no. 1, Bentham Science Publishers Ltd.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #122935v1